Bleeding and Platelet Disorders
Show Only Open Trials
1.
A Phase II, Single-Blind, Randomised, Placebo-Controlled Trial to Study the Efficacy and Safety of Anti-von Willebrand Factor Nanobody Administered as Adjunctive Treatment to Patients With Acquired Thrombotic Thrombocytopenic Purpura
- Study Status: Open to Enrollment
- Sponsor: Ablynx
- Disease Status and/or Stage: Thrombotic Thrombocytopenic Purpura (TPP)
